Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven versus Lipofundin LCT/MCT for parenteral nutrition-associated cholestasis in children
2008-008689-11Phase 3Terminated
- Sponsor
- Children's Memorial Health Institute
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intestinal failure-associated liver disease (IFALD) and cholestasis comparing Omegaven arm with Lipofundin LCT/MCT arm (2 arms). Primary endpoint: Incidence of cholestasis reversal. Started Mar 2009; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acidsoybean oil + medium-chain triglycerides
03
Conditions
intestinal failure-associated liver disease (IFALD)cholestasis
Beyond the preview
Go deeper on 2008-008689-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008689-11.